1548.HK
1548.HK
KYG3825B1059
GENSCRIPT BIO
Loading chart...

Company Profile

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.

Related stocks

1177.HK
1177.HK • Hong Kong SAR China
SBP GROUP
5.41 HKD
12.28B USD 1Y -31.5%
3696.HK
3696.HK • Hong Kong SAR China
INSILICO
49 HKD
3.61B USD
300759.SZ
300759.SZ • China
PHARMARON
43.11 CNY
11.85B USD 1Y +22.1%
196170.KQ
196170.KQ • South Korea
Alteogen
241,000 KRW
12.53B USD 1Y -33.6%
0126Z0.KS
0126Z0.KS • South Korea
SAMSUNG EPIS HOLDINGS
340,500 KRW
6.32B USD
3759.HK
3759.HK • China
PHARMARON
30.6 HKD
7.16B USD 1Y +9.4%
688331.SS
688331.SS • China
REMEGEN CO LTD
107.86 CNY
9.11B USD 1Y +4.2%
ANTHEM.NS
ANTHEM.NS • India
ANTHEM BIOSCIENCES LTD
862.3 INR
5B USD 1Y +13.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
64.6% p.a.
Max Drawdown (5Y)
-80.3%
Sharpe Ratio (5Y)
0.08
Beta Factor
0.81
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 588.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -80.4% in the extended horizon.
ende